A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
ViroMissile, Inc.
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Eli Lilly and Company
Poseida Therapeutics, Inc.
MacroGenics
SN BioScience
Cue Biopharma
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
MOMA Therapeutics
Actym Therapeutics, Inc.
EtiraRx Australia Pty Ltd
Exelixis
GONGCHU Biotechnology Co., Ltd
Bicara Therapeutics
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Novita Pharmaceuticals, Inc.
University Hospital, Ghent
NextPoint Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Monopar Therapeutics
Monopar Therapeutics
Exelixis
Molecure S.A.
Carisma Therapeutics Inc
Acepodia Biotech, Inc.
Eli Lilly and Company
Revolution Medicines, Inc.
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
Danatlas Pharmaceuticals Co., Ltd
Pfizer
Nerviano Medical Sciences
UTC Therapeutics Inc.
Xencor, Inc.
ADC Therapeutics S.A.
University Hospital, Geneva
University Medical Center Groningen
Qurgen Inc.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics